Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is well-positioned in the healthcare industry as a leading healthcare services company, with a strong focus on value-based care and population health management. The company's services, including specialty care management in oncology, cardiology, and musculoskeletal markets, as well as an integrated platform for health plan administration, provide a holistic approach to improving clinical and financial outcomes for its partners. With a solid track record of execution and a diverse client base, we believe Evolent has the potential for continued growth and impressive margins in the future.

Bears say

Evolent Health is facing several concerns, including rising healthcare costs and potential margin erosion due to its exposure to value-based care and government-sponsored insurance programs. While the company has a strong pipeline and successful implementations, the timing of contracts and conservatism in membership expectations could impact revenue growth. Furthermore, its regulatory risks and lack of accounting for preferred stock dividends also pose potential risks to its financial performance. Overall, the negative outlook is due to the uncertainty and challenges faced by Evolent Health in the current healthcare landscape, making it a risky investment.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.